Quality assessment of atopic dermatitis clinical practice guidelines in ≤ 18 years
- 10 November 2017
- journal article
- research article
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 310 (1) , 29-37
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease that affects the patients’ quality of life greatly often from a very young age. Its worldwide incidence in children and adults varies, but it is usually among the first ten causes of dermatological consultation worldwide. There is a wide variety of treatment options for this condition including topical and systemic regimes. The decision to choose a treatment option in dermatological diseases is greatly influenced by the personal experience of each specialist, which increases variability in the selection of available therapies. Clinical practice guidelines (CPGs) not only offer recommendations supported on the available scientific evidence, but also are intended to assist in making appropriate decisions in clinical scenarios. To standardize the way in which CPGs should be developed, an instrument called AGREE II (Appraisal of Guidelines for Research and Evaluation) is used. In this study, ten clinical practice guidelines in ≤ 18 years were evaluated. Six domains (scope and purpose, stakeholder involvement, rigor of development, clarity and presentation, applicability, and editorial independence) were assessed for each guideline, by three reviewers. Most of the domains obtained high scores except in the applicability domain. It is suggested that future atopic dermatitis CPGs should emphasize in the facilitating factors and barriers that may influence the application of guideline recommendations.Keywords
Funding Information
- Group of Investigative Dermatology (GRID)
This publication has 77 references indexed in Scilit:
- Investigating International Time Trends in the Incidence and Prevalence of Atopic Eczema 1990–2010: A Systematic Review of Epidemiological StudiesPLOS ONE, 2012
- AGREE II: advancing guideline development, reporting and evaluation in health careCanadian Medical Association Journal, 2010
- Development of the AGREE II, part 1: performance, usefulness and areas for improvementCanadian Medical Association Journal, 2010
- A systematic review of health-related quality of life in cutaneous melanomaAnnals of Oncology, 2009
- What is “quality of evidence” and why is it important to clinicians?BMJ, 2008
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Management of atopic eczema in children aged up to 12 years: summary of NICE guidanceBMJ, 2007
- Treatment of recalcitrant atopic dermatitis with omalizumabJournal of the American Academy of Dermatology, 2006
- Infliximab in the treatment of moderate to severe atopic dermatitisJournal of the American Academy of Dermatology, 2005
- Guidelines of care for atopic dermatitisJournal of the American Academy of Dermatology, 2004